Knight Therapeutics Inc. GUD.TO
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About GUD.TO
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Knight Therapeutics Inc. is a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, marketing, and commercializing prescription medicines, primarily for underserved or niche therapeutic markets. The company operates within the branded pharmaceutical and specialty healthcare industries, with a strategic emphasis on Latin America and Canada. Its revenue is primarily generated through the sale and distribution of branded pharmaceuticals, licensing agreements, and milestone or royalty-related arrangements tied to its product portfolio.
Knight Therapeutics was founded in 2014 by Jonathan Ross Goodman, who previously led Paladin Labs before its acquisition by Endo International. The company was established with a business model centered on capital-efficient pharmaceutical acquisitions and regional commercialization partnerships. Over time, Knight expanded from a Canada-focused specialty pharmaceutical platform into a broader pan-Latin American operation through acquisitions and regional investments. The company positions itself as a specialty pharmaceutical partner with strong regional infrastructure, local regulatory expertise, and an asset-light operating approach focused on in-licensed and acquired products rather than large-scale internal drug discovery.
Business Operations
Knight Therapeutics operates through pharmaceutical commercialization and distribution activities across Canada and Latin America, with its operations increasingly concentrated in Latin America following a series of acquisitions and regional expansions. The company markets therapies across several therapeutic areas, including hematology, oncology, infectious diseases, neurology, and rare diseases. Revenue is generated through direct product sales, distribution agreements, licensing arrangements, and royalties from partnered products. Its business model relies heavily on obtaining regional rights to established or late-stage pharmaceutical products and leveraging local commercial infrastructure for market access.
The company controls a portfolio of pharmaceutical assets and regional commercialization rights through subsidiaries and operating entities across multiple countries. Key operating platforms include Knight Therapeutics International S.A., United Medical, and regional pharmaceutical distribution operations in countries such as Brazil, Mexico, Colombia, and Argentina. Knight has maintained partnerships with international pharmaceutical developers and biotechnology companies seeking access to Latin American markets. The company also utilizes regional regulatory, logistics, and sales capabilities as strategic assets supporting commercialization efficiency and market penetration.
Strategic Position & Investments
Knight Therapeutics has pursued a long-term strategy centered on expanding its specialty pharmaceutical presence in Latin America through acquisitions, licensing transactions, and regional infrastructure investments. A major strategic milestone was the acquisition of Grupo Biotoscana and related Latin American assets, which significantly expanded the company’s commercial footprint and transformed it into a broader regional pharmaceutical operator. The company has also completed investments in product portfolios and commercialization rights intended to strengthen its therapeutic coverage in oncology, hematology, and specialty care.
The company continues to prioritize growth through selective acquisitions, in-licensing opportunities, and partnerships with international pharmaceutical firms seeking regional commercialization support. Knight has invested in healthcare and life sciences opportunities through equity positions and strategic financing activities, although its primary focus remains specialty pharmaceutical commercialization rather than drug discovery research. Emerging strategic areas include biologics, specialty hospital products, and therapies targeting rare or complex diseases, particularly within Latin American healthcare systems where access to innovative medicines remains uneven.
Geographic Footprint
Knight Therapeutics is headquartered in Montreal, Quebec, Canada, and maintains a substantial operational presence throughout Latin America. Its commercial activities span multiple countries including Brazil, Mexico, Colombia, Argentina, Chile, Peru, and other regional markets. Canada remains part of its operating footprint, although the company’s strategic and revenue focus has increasingly shifted toward Latin American markets due to growth opportunities and regional acquisitions.
The company’s international operations provide exposure to both public and private healthcare systems across emerging markets. Through local subsidiaries, distribution networks, and regulatory capabilities, Knight maintains influence across several major pharmaceutical markets in the region. Its operational strategy emphasizes regional diversification, localized market expertise, and scalable infrastructure capable of supporting additional in-licensed products and pharmaceutical partnerships.
Leadership & Governance
Knight Therapeutics was founded by Jonathan Ross Goodman, who has remained closely associated with the company’s strategic direction and long-term development. Leadership has emphasized disciplined capital allocation, regional pharmaceutical consolidation, and expansion through partnerships and acquisitions rather than high-risk research and development spending. The company’s governance approach reflects its focus on shareholder value, specialty pharmaceutical growth, and regional market expansion.
Key executives include:
- Samira Sakhia – President and Chief Executive Officer
- Jonathan Ross Goodman – Executive Chairman
- Didier Busque – Chief Financial Officer
- Ariel Burschtin – Chief Operating Officer, Latin America
- Carole Benchetrit – Chief Legal Officer and Corporate Secretary
The company’s leadership strategy has consistently emphasized operational scalability in Latin America, disciplined acquisition integration, and leveraging regional expertise to commercialize specialized pharmaceutical products across fragmented healthcare markets.